Bayview Research Group — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$7,413	2
2023	Research	$346	1
2022	Research	$1,622	3
2021	Research	$69,921	18
2020	Research	$159,249	24
2019	Research	$1,170,757	62

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $822,991 83 payments
Pfizer Inc. $553,433 22 payments
OPKO Pharmaceuticals, LLC $32,884 5 payments

Studies the money was for Research payments · program years 2019–2025

M16-100 $658,973 30 payments
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $452,518 13 payments
A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $97,156 7 payments
M16-283 $85,573 28 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $64,062 11 payments
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) $32,884 5 payments
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $5,858 7 payments
M16-283 - Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $4,000 1 payment
A Phase 3 Study to Evaluate the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults 60 Years of Age and Older $3,413 1 payment
M12-817 $2,902 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.